Sun Pharma poor Q1 FY16 – Ranbaxy integration blues

Sun Pharma announced its Q1’FY16 nos. post market hours today. As expected, they were bad on profitability front on account of Ranbaxy integration charges. On account of Ranbaxy integration issues the drug major had already issued profit warning on 20th July. Net profit fell 60 percent YoY to 479 crore in Q1. Although revenues grew 6.7 percent YoY and EBITDA margins at 27.5 percent were also better than what market expected. Last quarter margins were disastrous at 14.5 percent. All in all, it was a mixed quarter for Sun Pharma. Ranbaxy continues to be the pain point for the drug major. Market already knew about the poor results on account of profit warning issued by company last month. So stock should not react in a big way tomorrow.

I had entered into ratio spreads in Sun pharma in July – Bought one lot of 940 call and sold 10 lots of 960 & 980 calls August series. Looks like tomorrow will be the right time to square off these ratio spreads.

Disclaimer: These are my personal views and you should do your own due diligence before acting on anything written in this blog. Please take reasonable care while trading in options, especially while selling. I am not advising anyone to sell or buy options. My purpose of writing this blog is to highlight my trading strategies


0 Responses to “Sun Pharma poor Q1 FY16 – Ranbaxy integration blues”

  1. Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

August 2015
« Jun    

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 233 other followers


Top Posts & Pages

%d bloggers like this: